[PDF][PDF] Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group
C Langebrake, U Creutzig, M Dworzak… - Journal of Clinical …, 2006 - researchgate.net
Journal of Clinical Oncology, 2006•researchgate.net
Purpose Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid
leukemia (AML) may predict outcome. However, the optimal time points for investigation, the
best antibody combinations, and most importantly, the clinical impact of RD analysis remain
unclear.
leukemia (AML) may predict outcome. However, the optimal time points for investigation, the
best antibody combinations, and most importantly, the clinical impact of RD analysis remain
unclear.
Purpose
Monitoring of residual disease (RD) by flow cytometry in childhood acute myeloid leukemia (AML) may predict outcome. However, the optimal time points for investigation, the best antibody combinations, and most importantly, the clinical impact of RD analysis remain unclear.
researchgate.net
